For research use only. Not for therapeutic Use.
Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke[1][2].
Glenzocimab (0-100000 ng/mL) inhibits GPVI-Fc binding to collagen immobilized on a microtitration plate with an IC50 of 1.37 μg/mL[2].
Glenzocimab (1-8 mg/kg; i.v.) inhibits collagen-induced platelet aggregation in cynomolgus monkeys[2].
| Catalog Number | I041848 |
| CAS Number | 2101829-58-5 |
| Purity | ≥95% |
| Reference | [1]. Wichaiyo S, et al. Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. Stroke. 2022 Nov;53(11):3506-3513. [2]. Lebozec K, et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks. MAbs. 2017 Aug/Sep;9(6):945-958. |
